Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study

<div>The overall percentage change in target lesion of the 39 patients with advanced gastric cancer who received apatinib plus PD-1 inhibitor administration (gray columns were PR, black columns were SD, and yellow columns were PD).</div>

Disease Markers

fig2

Figure 2

Figure 2: Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study 